U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Nucleic Acid
Created
by admin
on Fri Jun 25 21:35:30 UTC 2021
Edited
by admin
on Fri Jun 25 21:35:30 UTC 2021
Nucleic Acid Type mRNA VACCINE
Nucleic Acid Subtype TRANSGENE
Sequence Origin VIRAL
Sequence Type COMPLETE
Record UNII
5085ZFP6SJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RNA INGREDIENT BNT-162B2
Preferred Name English
BNT162B2
Preferred Name English
BNT-162B2
Preferred Name English
TOZINAMERAN
INN  
Official Name English
RNA (RECOMBINANT 5'-(1,2-((3'-O-METHYL)M7G-(5'->5')-PPP-AM))-CAPPED ALL URIDINE->N1-METHYLPSEUDOURIDINE-SUBSTITUTED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SECRETORY SIGNAL PEPTIDE CONTG. SPIKE GLYCOPROTEIN S1S2-SPECIFYING PLUS 5'-AND 3'-UNTRANSL
Common Name English
PFIZER COVID-19 VACCINE
Common Name English
COMIRNATY
Brand Name English
TOZINAMERAN [WHO-DD]
Common Name English
TOZINAMERAN [INN]
Common Name English
Code System Code Type Description
INN
11889
Created by admin on Fri Jun 25 21:35:30 UTC 2021 , Edited by admin on Fri Jun 25 21:35:30 UTC 2021
PRIMARY
FDA UNII
5085ZFP6SJ
Created by admin on Fri Jun 25 21:35:30 UTC 2021 , Edited by admin on Fri Jun 25 21:35:30 UTC 2021
PRIMARY
NCI_THESAURUS
C173055
Created by admin on Fri Jun 25 21:35:30 UTC 2021 , Edited by admin on Fri Jun 25 21:35:30 UTC 2021
PRIMARY
CAS
2417899-77-3
Created by admin on Fri Jun 25 21:35:30 UTC 2021 , Edited by admin on Fri Jun 25 21:35:30 UTC 2021
PRIMARY
Sugar Site Range Site Count
D-Ribose (RNA) 1_2-1_4283 4282 / 4283
2'-O-Methyl-Ribose 1_1 1 / 4283
Linkage Site Range Site Count
Phosphate 1_2-1_4283 4282 / 4282
Related Record Type Details
TARGET ORGANISM->VACCINE ANTIGEN
APPEARS TO HAVE COMPARABLE EFFICACY TO NON-VARIANT STRAIN
TARGET ORGANISM->VACCINE ANTIGEN
From 7 days after second dose to a median time of 2 months.
EFFICACY
EXPRESSED PROTEIN->VECTOR
EXPRESSED PROTEIN->VECTOR
TARGET ORGANISM->VACCINE ANTIGEN
SERUM NEUTRALIZING ABILIT
Related Record Type Details
ACTIVE MOIETY
Designed to produce neutralizing antibody to the SARS-CoV-2 S glycoprotein. The intention is that such antibodies would protect against SARS-CoV-2 infection and its resulting disease, COVID-19

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
NUCLEOTIDE SUBSTITUTION [1_1] 5'-TERMINUS MRNA CAP M7G+M3'-5'-PPP-5'-AM2'-3'-P- VNP8CZY34V
NUCLEOSIDE_SUBSTITUTION RESIDUE_SPECIFIC N1-METHYLPSEUDOURIDINE 09RAD4M6WF
Name Property Type Amount Referenced Substance Defining Parameters References
5'-UTR sequence of the human alpha-globin mRNA with an optimized ?Kozak sequence? NUCLEIC ACID FEATURE
SARS-COV2 SPIKE CODING SEQUENCE NUCLEIC ACID FEATURE